These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34551507)

  • 1. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
    Verstovsek S; Mesa R; Talpaz M; Kiladjian JJ; Harrison CN; Oh ST; Vannucchi AM; Rampal R; Scott BL; Buckley SA; Craig AR; Roman-Torres K; Mascarenhas JO
    Haematologica; 2022 Jul; 107(7):1599-1607. PubMed ID: 34551507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
    Mascarenhas J
    Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
    Mesa RA; Vannucchi AM; Mead A; Egyed M; Szoke A; Suvorov A; Jakucs J; Perkins A; Prasad R; Mayer J; Demeter J; Ganly P; Singer JW; Zhou H; Dean JP; Te Boekhorst PA; Nangalia J; Kiladjian JJ; Harrison CN
    Lancet Haematol; 2017 May; 4(5):e225-e236. PubMed ID: 28336242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
    Tremblay D; Mascarenhas J
    Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
    Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
    J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
    Jain T; Mesa R
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
    Diaz AE; Mesa RA
    Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing patients with myelofibrosis and thrombocytopenia.
    Yilmaz M; Verstovsek S
    Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
    Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
    Tremblay D; Mesa R; Scott B; Buckley S; Roman-Torres K; Verstovsek S; Mascarenhas J
    Blood Adv; 2020 Dec; 4(23):5929-5935. PubMed ID: 33275766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
    Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
    Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The odyssey of pacritinib in myelofibrosis.
    Venugopal S; Mascarenhas J
    Blood Adv; 2022 Aug; 6(16):4905-4913. PubMed ID: 35622972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
    Stein BL
    Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
    Tremblay D; Mascarenhas J
    Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to tackle cytopenic myelofibrosis.
    Reynolds SB; Pettit K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pacritinib for myelofibrosis in adults with thrombocytopenia.
    Yang DH; Lu Q; Zhu Z; Huang G; Young K
    Drugs Today (Barc); 2022 Dec; 58(12):577-589. PubMed ID: 36651066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pacritinib: a new agent for the management of myelofibrosis?
    Beauverd Y; McLornan DP; Harrison CN
    Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.
    Mascarenhas J; Virtgaym E; Stal M; Blacklock H; Gerds AT; Mesa R; Ganly P; Snyder D; Tabbara I; Tremblay D; Moshier E
    Ann Hematol; 2018 Aug; 97(8):1369-1374. PubMed ID: 29616317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.